T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.

(Cell 185, 1041–1051.e1–e6; March 17, 2022)

In our originally published article, an error in production resulted in mistakes to the citations and references for Garcia-Beltran et al., 2021a, 2021b, and 2022. At publication, Garcia-Beltran et al., 2021a referred to the Correction for the original Garcia-Beltran et al., 2021a, which ran in Cell volume 184 on page 2532; instead, it should refer to the original article, which ran in Cell volume 184 on pages 2372–2383.e9. Garcia-Beltran et al., 2021b referred to the BioRxiv pre-print publication of Garcia-Beltran et al., 2022; instead, it should refer to Garcia-Beltran et al., 2021, Cell 184, 476–488.e11. The references have now been corrected online.

To coincide with corrections to the references, the citations in the following sentences have also been corrected as indicated:

• “Additional booster vaccine doses partially compensate for this effect (Garcia-Beltran et al., 2021b; Hoffmann et al., 2021)” now refers to Garcia-Beltran et al. (2022).

• “Within this cohort of individuals, we recently reported markedly reduced neutralization of Omicron following primary series vaccination, which was overcome by additional ‘booster’ doses (Garcia-Beltran et al., 2021b)” now refers to Garcia-Beltran et al. (2022).

• “Using a pseudoneutralization titer threshold of 20 (Garcia-Beltran et al., 2022)” now refers to Garcia-Beltran et al. (2021b).

• In Figure 4D, “Dotted lines denote a pseudoneutralization titer threshold of 20 (Garcia-Beltran et al., 2021c)” now refers to Garcia-Beltran et al. (2021b).

• “The SARS-CoV-2 Omicron variant demonstrates substantial escape from neutralizing antibody responses (Garcia-Beltran et al., 2021b; Hoffmann et al., 2021)” now refers to Garcia-Beltran et al. (2022).

The journal apologizes for any confusion these errors may have caused.